Langdon L. Miller

14.0k total citations · 3 hit papers
65 papers, 7.6k citations indexed

About

Langdon L. Miller is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Langdon L. Miller has authored 65 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 32 papers in Molecular Biology and 24 papers in Genetics. Recurrent topics in Langdon L. Miller's work include Cancer therapeutics and mechanisms (19 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Lung Cancer Research Studies (10 papers). Langdon L. Miller is often cited by papers focused on Cancer therapeutics and mechanisms (19 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Lung Cancer Research Studies (10 papers). Langdon L. Miller collaborates with scholars based in United States, Italy and United Kingdom. Langdon L. Miller's co-authors include Gary Elfring, Paula K. Locker, Nicoletta Pirotta, Leonard B. Saltz, John V. Cox, Lee S. Rosen, Charles D. Blanke, Malcolm J. Moore, Stephen P. Ackland and Jean A. Maroun and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Langdon L. Miller

65 papers receiving 7.4k citations

Hit Papers

Irinotecan plus Fluoroura... 2000 2026 2008 2017 2000 2014 2011 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
    2000 2.4k citations John V. Cox, Paula K. Locker et al. New England Journal of Medicine profile →
  2. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
    2014 465 citations Jennifer R. Brown, Steven Coutré et al. Blood profile →
  3. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
    2011 442 citations Julia Hoellenriegel, Sarah Meadows et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Langdon L. Miller United States 29 4.0k 2.5k 1.8k 1.8k 1.4k 65 7.6k
Gunter Schuch Germany 27 2.8k 0.7× 1.8k 0.7× 1.5k 0.8× 480 0.3× 708 0.5× 68 5.0k
Emily K. Bergsland United States 45 7.1k 1.8× 3.1k 1.3× 1.8k 1.0× 429 0.2× 694 0.5× 202 10.9k
Lia Gore United States 43 2.6k 0.6× 2.6k 1.0× 821 0.5× 673 0.4× 763 0.6× 202 6.1k
Alexander Laird United States 32 1.7k 0.4× 2.7k 1.1× 1.2k 0.7× 434 0.2× 603 0.4× 97 4.9k
Francesco Cognetti Italy 46 5.0k 1.2× 2.4k 1.0× 2.3k 1.3× 525 0.3× 558 0.4× 221 8.5k
Maurizio Martini Italy 44 1.9k 0.5× 2.3k 0.9× 1.1k 0.6× 1.3k 0.8× 788 0.6× 281 6.5k
Lowell L. Hart United States 37 3.5k 0.9× 1.7k 0.7× 2.2k 1.3× 267 0.2× 480 0.4× 127 5.5k
Mohamed Hebbar France 37 2.0k 0.5× 1.2k 0.5× 761 0.4× 248 0.1× 684 0.5× 151 4.6k
P Sismondi Italy 47 2.7k 0.7× 1.7k 0.7× 834 0.5× 411 0.2× 952 0.7× 188 6.9k
Michael N. Needle United States 31 2.5k 0.6× 1.0k 0.4× 1.9k 1.0× 1.1k 0.6× 485 0.4× 72 5.3k

Countries citing papers authored by Langdon L. Miller

Since Specialization
Citations

This map shows the geographic impact of Langdon L. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Langdon L. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Langdon L. Miller more than expected).

Fields of papers citing papers by Langdon L. Miller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Langdon L. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Langdon L. Miller. The network helps show where Langdon L. Miller may publish in the future.

Co-authorship network of co-authors of Langdon L. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Langdon L. Miller. A scholar is included among the top collaborators of Langdon L. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Langdon L. Miller. Langdon L. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Furman, Richard R., Jacqueline C. Barrientos, Jeff P. Sharman, et al.. (2012). A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 30(15_suppl). 6518–6518. 21 indexed citations
2.
Hoellenriegel, Julia, Sarah Meadows, Mariela Sivina, et al.. (2011). The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 118(13). 3603–3612. 442 indexed citations breakdown →
3.
Kerem, Eitan, Michael Wilschanski, Thea Pugatsch, et al.. (2011). Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosis. Journal of Cystic Fibrosis. 10(3). 193–200. 11 indexed citations
4.
5.
Sermet‐Gaudelus, Isabelle, K. De Boeck, Georges Casimir, et al.. (2010). Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 182(10). 1262–1272. 184 indexed citations
6.
McDonald, Craig M., Erik Henricson, Jay J. Han, et al.. (2010). The 6‐minute walk test in Duchenne/Becker muscular dystrophy: Longitudinal observations. Muscle & Nerve. 42(6). 966–974. 131 indexed citations
7.
McDonald, Craig M., Erik Henricson, Jay J. Han, et al.. (2009). The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle & Nerve. 41(4). 500–510. 283 indexed citations
8.
Kerem, Eitan, Samit Hirawat, S. Armoni, et al.. (2008). Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. The Lancet. 372(9640). 719–727. 290 indexed citations
9.
Buyse, Marc, Tomasz Burzykowski, Kevin Carroll, et al.. (2007). Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer. Journal of Clinical Oncology. 25(33). 5218–5224. 267 indexed citations
10.
Cloughesy, Timothy F., Emese Filka, John G. Kuhn, et al.. (2003). Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer. 97(S9). 2381–2386. 88 indexed citations
11.
Hudes, Gary R., Naomi B. Haas, Per Olov Gunnarsson, et al.. (2002). Phase I Clinical and Pharmacologic Trial of Intravenous Estramustine Phosphate. Journal of Clinical Oncology. 20(4). 1115–1127. 3 indexed citations
12.
Socinski, Mark A., Alan B. Sandler, Valerie K. Israel, et al.. (2002). Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma. Cancer. 95(7). 1520–1527. 15 indexed citations
13.
Slatter, J. Greg, Larry J. Schaaf, James P. Sams, et al.. (2000). Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) Following I.V. Infusion of [14C]CPT-11 in Cancer Patients. Drug Metabolism and Disposition. 28(4). 423–433. 241 indexed citations
14.
Rothenberg, Mace L., John V. Cox, Russell F. DeVore, et al.. (1999). A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 85(4). 786–795. 162 indexed citations
15.
16.
Janik, John E., Langdon L. Miller, William C. Kopp, et al.. (1999). Treatment with Tumor Necrosis Factor-α and Granulocyte–Macrophage Colony-Stimulating Factor Increases Epidermal Langerhans' Cell Numbers in Cancer Patients. Clinical Immunology. 93(3). 209–221. 19 indexed citations
17.
Curti, Brendan D., Walter J. Urba, Dan L. Longo, et al.. (1996). Endocrine Effects of IL-1α and β Administered in a Phase I Trial to Patients with Advanced Cancer. Journal of Immunotherapy. 19(2). 142–148. 17 indexed citations
18.
Curti, Brendan D., Augusto C. Ochoa, Walter J. Urba, et al.. (1996). Influence of Interleukin-2 Regimens on Circulating Populations of Lymphocytes After Adoptive Transfer of Anti-CD3-Stimulated T Cells. Journal of Immunotherapy. 19(4). 296–308. 17 indexed citations
19.
Smith, John W., W. Gregory Alvord, John E. Janik, et al.. (1993). The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin. New England Journal of Medicine. 328(11). 756–761. 98 indexed citations
20.
Korn, Edward L., Kai Yu, & Langdon L. Miller. (1993). Stopping a clinical trial very early because of toxicity: Summarizing the evidence. Controlled Clinical Trials. 14(4). 286–295. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gunter Schuch Breakdown of academic impact, for papers by Emily K. Bergsland Breakdown of academic impact, for papers by Lia Gore Breakdown of academic impact, for papers by Alexander Laird Breakdown of academic impact, for papers by Francesco Cognetti Breakdown of academic impact, for papers by Maurizio Martini Breakdown of academic impact, for papers by Lowell L. Hart Breakdown of academic impact, for papers by Mohamed Hebbar Breakdown of academic impact, for papers by P Sismondi Breakdown of academic impact, for papers by Michael N. Needle
Rankless by CCL
2026